down arrow

Orchestra Biomed Holdings, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US68572M1062
  • NASDAQ: HSAQ
USD
5.93
-0.29 (-4.66%)

Sep 23

NAS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
CareDx, Inc.
Tactile Systems Technology, Inc.
Surmodics, Inc.
Pulmonx Corp.
AirSculpt Technologies, Inc.
Organogenesis Holdings, Inc.
Utah Medical Products, Inc.
CVRx, Inc.
Nano-X Imaging Ltd.
Orchestra Biomed Holdings, Inc.
OraSure Technologies, Inc.

Why is Orchestra Biomed Holdings, Inc. ?

1
Negative results in Jun 26
  • NET SALES(HY) At USD 0.2 MM has Grown at -88.38%
  • ROCE(HY) Lowest at -397.3%
  • RAW MATERIAL COST(Y) Grown by 145.94% (YoY)
2
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 152.34%, its profits have risen by 13.1%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Orchestra Biomed Holdings, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Orchestra Biomed Holdings, Inc.
152.34%
-0.37
69.83%
S&P 500
15.76%
1.20
13.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
142.32%
EBIT Growth (5y)
-366.47%
EBIT to Interest (avg)
-36.76
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-2.07
Sales to Capital Employed (avg)
0.10
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
50.19%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.93
EV to EBIT
-3.36
EV to EBITDA
-3.39
EV to Capital Employed
-14.98
EV to Sales
5.21
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-83.55%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

10What is working for the Company
NET PROFIT(HY)

Higher at USD -44.73 MM

DEBTORS TURNOVER RATIO(HY)

Highest at 477.25 times

NET SALES(9M)

Higher at USD 31.12 MM

-23What is not working for the Company
NET SALES(HY)

At USD 0.2 MM has Grown at -88.38%

ROCE(HY)

Lowest at -397.3%

RAW MATERIAL COST(Y)

Grown by 145.94% (YoY

INTEREST(Q)

Highest at USD 1.77 MM

OPERATING PROFIT(Q)

Lowest at USD -22.26 MM

PRE-TAX PROFIT(Q)

Lowest at USD -24.08 MM

NET PROFIT(Q)

Lowest at USD -24.08 MM

Here's what is working for Orchestra Biomed Holdings, Inc.

Debtors Turnover Ratio
Highest at 477.25 times and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Here's what is not working for Orchestra Biomed Holdings, Inc.

Net Sales
At USD 0.2 MM has Grown at -88.38%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very negative

Net Sales (USD MM)

Pre-Tax Profit
At USD -24.08 MM has Fallen at -75.58%
over average net sales of the previous four periods of USD -13.71 MM
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit
At USD -24.08 MM has Fallen at -75.58%
over average net sales of the previous four periods of USD -13.71 MM
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (USD MM)

Interest
At USD 1.77 MM has Grown at 115.35%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Interest
Highest at USD 1.77 MM
in the last five periods and Increased by 115.35% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Operating Profit
Lowest at USD -22.26 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (USD MM)

Pre-Tax Profit
Lowest at USD -24.08 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit
Lowest at USD -24.08 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is negative

Net Profit (USD MM)

Raw Material Cost
Grown by 145.94% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Footer loading